CD73 expression as a resistance mechanism in advanced EGFR-mutated non-small cell lung cancer
We demonstrated differential expression patterns among the immune markers and higher levels of CD73 in cases with non-T790M-resistance to EGFR-TKIs. Although a limited number of cases were included in these analyses, the results might point to a potential role of immune markers inducing an immunosuppressive environment and thereby contribute to development of resistance to TKIs, which in turn could have future therapeutic implications.
Authors
- Anne Pernille Harlem Dyrbekk (ORCID: https://orcid.org/0009-0008-7930-9153)
- Philip Martin (ORCID: https://orcid.org/0000-0002-8456-9725)
- Ina Bisha (ORCID: https://orcid.org/0009-0009-8609-6376)
- Inger Johanne Zwicky Eide (ORCID: https://orcid.org/0000-0003-1246-3048)
- Odd Terje Brustugun (ORCID: https://orcid.org/0000-0002-5153-8391)
- Zachary A. Cooper (ORCID: https://orcid.org/0000-0003-1059-0940)
- Sotirios Lakis
- Thomas Haberichter
- Arthur Lewis
- Jessica Chan
Institutions
- University of Oslo (NO)
- Vestre Viken Hospital Trust (NO)
- Sykehuset i Vestfold (NO)
- AstraZeneca (Singapore) (SG)
- AstraZeneca (Brazil) (BR)
- Cancer Genetics (United States) (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-03-03
- DOI
- https://doi.org/10.3389/fonc.2026.1755595
- Primary Topic
- Adenosine and Purinergic Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- Helse Sør-Øst RHF